Bayer to Maintain 2012 R&D Budget at $4B

German drugmaker Bayer aims to invest around $4.07 billion into R&D in the current year; and for 2012, investments of a comparable level are planned, as newspaper reports.

The business newspaper Financial Times Deutschland reports that Bayer's internal papers indicate the German pharma giant will maintain its investment in R&D at just above $4 billion in 2012, keeping it match with the 2011 budget. The bulk of that money is devoted to healthcare, with about a third of the cash earmarked for crop and material science.

Related News

News CPHI Milan 2024 - From the Floor

Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at...

7 Oct 2024
News The BIOSECURE Act: implications for the pharma supply chain

On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin...

20 Sep 2024
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing

The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective.

3 Sep 2024
News CPHI Milan Speaker Spotlight: CDMO relations with Pharma and Start-Ups

In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences.

28 Aug 2024
News Women in Pharma: Advocating for trans healthcare in pharma

In our monthly series on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond.

30 Jul 2024
News Updated – Changing abortion pill access according to the US FDA and Supreme Court

After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug.

14 Jun 2024
News CPHI North America 2024 – From the Floor

Welcome to Philly! CPHI North America once again graces the Philadelphia Convention Center, 7–9 May 2024.

1 May 2024
News Drug Patent Expiries: a steep cliff or opportunity for innovation?

The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future.

30 Apr 2024

CPHI Online is the largest global marketplace in the pharma ingredients industry

Bayer to Maintain 2012 R&D Budget at $4B

Related News

Position your company at the heart of the global Pharma industry with a CPHI Online membership

Request for general information

Send a message to Please review your profile details to ensure it is up-to-date.

Send a message to
Please review your profile details to ensure it is up-to-date.